-
1
-
-
0032983666
-
Study (UKPDS) Group. UKPDS 49. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies.
-
U.K. Prospective Diabetes
-
U.K. Prospective Diabetes. Study (UKPDS) Group. UKPDS 49. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA 1999; 281: 2005-2012.
-
(1999)
JAMA
, vol.281
, pp. 2005-2012
-
-
-
2
-
-
0028817815
-
UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective
-
U.K. Prospective Diabetes Study Group (UKPDS)
-
U.K. Prospective Diabetes Study Group (UKPDS). UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes 1995; 44: 1249-1258.
-
(1995)
Diabetes
, vol.44
, pp. 1249-1258
-
-
-
3
-
-
0034641568
-
UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study.
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. BMJ 2000; 321: 405-412.
-
(2000)
BMJ
, vol.321
, pp. 405-412
-
-
-
4
-
-
1042280201
-
Glycemic control from 1998 to 2000 among U.S. adults diagnosed with type 2 diabetes.
-
Koro CE, Bowlin SJ, Bourgeois B, Fedder DO. Glycemic control from 1998 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 2004; 27: 17-20.
-
(2004)
Diabetes Care
, vol.27
, pp. 17-20
-
-
Koro, C.E.1
Bowlin, S.J.2
Bourgeois, B.3
Fedder, D.O.4
-
5
-
-
84878665227
-
-
ACE/AACE Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Available from URL: Accessed September 2009.
-
ACE/AACE Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Available from URL: Accessed September 2009.
-
-
-
-
6
-
-
0347480396
-
Clinical use of thiazolidinediones: Recommendations.
-
Abrahamson MJ. Clinical use of thiazolidinediones: Recommendations. Am J Med 2003: 115: 117S-120S.
-
(2003)
Am J Med
, vol.115
-
-
Abrahamson, M.J.1
-
7
-
-
33749498694
-
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
-
Rosenstock J, Rood J, Cobitz A et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006; 8:650-660.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 650-660
-
-
Rosenstock, J.1
Rood, J.2
Cobitz, A.3
-
8
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
-
for the ADOPT Study Group
-
Kahn SE, Haffner SM, Heise MA et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
-
(2006)
N Engl J Med
, vol.355
, pp. 2427-2443
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
-
9
-
-
48649095960
-
Rosiglitazone-associated fracture in type 2 diabetes.
-
for the ADOPT Study Group
-
Kahn SE, Zinman B, Lachin JM et al. for the ADOPT Study Group. Rosiglitazone-associated fracture in type 2 diabetes. Diabetes Care 2008; 31: 845-851.
-
(2008)
Diabetes Care
, vol.31
, pp. 845-851
-
-
Kahn, S.E.1
Zinman, B.2
Lachin, J.M.3
-
10
-
-
67149146438
-
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
-
Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
-
(2009)
Lancet
, vol.373
, pp. 2125-2135
-
-
Home, P.D.1
Pocock, S.J.2
Beck-Nielsen, H.3
-
11
-
-
0032511583
-
UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.
-
U.K. Prospective Diabetes Study Group (UKPDS)
-
U.K. Prospective Diabetes Study Group (UKPDS). UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
12
-
-
0032511566
-
UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes.
-
U.K. Prospective Diabetes Study Group (UKPDS)
-
U.K. Prospective Diabetes Study Group (UKPDS). UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-865.
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
-
13
-
-
0037116638
-
Oral antihyperglycemic therapy for type 2 diabetes.
-
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287: 360-372.
-
(2002)
JAMA
, vol.287
, pp. 360-372
-
-
Inzucchi, S.E.1
-
14
-
-
0012893593
-
Insulin resistance and B-cell function-a clinical perspective.
-
Matthews D. Insulin resistance and B-cell function-a clinical perspective. Diabetes Obes Metab 2001; 3(Suppl. 1): S28-33.
-
(2001)
Diabetes Obes Metab
, vol.3
, Issue.SUPPL. 1
-
-
Matthews, D.1
-
15
-
-
0001285263
-
Clinical practice recommendations.
-
ADA
-
ADA, Clinical practice recommendations. Diabetes Care 2010; 33(Suppl. 1): 1s-100s.
-
(2010)
Diabetes Care
, vol.33
, Issue.SUPPL. 1
-
-
-
16
-
-
0038064504
-
Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetes with metabolic syndrome.
-
Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetes with metabolic syndrome. Endocrine 2003; 20: 215-218.
-
(2003)
Endocrine
, vol.20
, pp. 215-218
-
-
Akbar, D.H.1
-
17
-
-
0037031267
-
Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
-
Haffner SM, Greenberg AS, Weston WM. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
-
(2002)
Circulation
, vol.106
, pp. 679-684
-
-
Haffner, S.M.1
Greenberg, A.S.2
Weston, W.M.3
-
18
-
-
0034999667
-
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.
-
1930-1935.
-
Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
-
(2001)
J Clin Endocrinol Metab
, vol.86
-
-
Weyer, C.1
Funahashi, T.2
Tanaka, S.3
-
19
-
-
0036481709
-
Synthetic peroxisome proliferators-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
-
Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferators-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.
-
(2002)
Diabetes Care
, vol.25
, pp. 376-380
-
-
Yang, W.S.1
Jeng, C.Y.2
Wu, T.J.3
-
20
-
-
14844327755
-
Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity?
-
Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity? Int J Obes 2005; 29: S17-23.
-
(2005)
Int J Obes
, vol.29
-
-
Bouskila, M.1
Pajvani, U.B.2
Scherer, P.E.3
-
21
-
-
61449206180
-
Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus.
-
Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009; 160: 265-273.
-
(2009)
Eur J Endocrinol
, vol.160
, pp. 265-273
-
-
Kanazawa, I.1
Yamaguchi, T.2
Yamamoto, M.3
Yamauchi, M.4
Yano, S.5
Sugimoto, T.6
-
22
-
-
34147154970
-
The peroxisome proliferator-activated receptor-agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial
-
Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 2007; 92: 1305-1310.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 1305-1310
-
-
Grey, A.1
Bolland, M.2
Gamble, G.3
-
23
-
-
34250847265
-
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.
-
Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007; 148: 2669-2680.
-
(2007)
Endocrinology
, vol.148
, pp. 2669-2680
-
-
Lazarenko, O.P.1
Rzonca, S.O.2
Hogue, W.R.3
Swain, F.L.4
Suva, L.J.5
Lecka-Czernik, B.6
-
24
-
-
0344061039
-
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
-
Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
-
(2003)
Diabetes Obes Metab
, vol.5
, pp. 163-170
-
-
Jones, T.A.1
Sautter, M.2
Van Gaal, L.F.3
Jones, N.P.4
-
25
-
-
0042670079
-
Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
-
Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 2003; 26: 1685-1689.
-
(2003)
Diabetes Care
, vol.26
, pp. 1685-1689
-
-
Fonseca, V.1
Grunberger, G.2
Gupta, S.3
Shen, S.4
Foley, J.E.5
|